Discovery of Therapeutics Targeting Oxidative Stress in Autosomal Recessive Cerebellar Ataxia: A Systematic Review

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 15; no. 6; p. 764
• Main Authors: Lew, Sze Yuen, Phang, Michael Weng Lok, Chong, Pit Shan, Roy, Jaydeep, Poon, Chi Him, Yu, Wing Shan, Lim, Lee Wei, Wong, Kah Hui
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 19.06.2022; MDPI
• Subjects: Age; antioxidant pathway and therapy; Antioxidants; Apraxia; Ataxia; autosomal recessive cerebellar ataxia; DNA damage; DNA repair; Dystonia; Genes; genetic mutation; Kinases; Mitochondrial DNA; Mutation; Oxidative stress; Pathogenesis; Peripheral neuropathy; preclinical model; Proteins; rare neurodegenerative disease; Strabismus; Systematic Review; Vitamin E; United States > US; Japan; Italy; North Africa; France; Tunisia; Germany
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph15060764

Autosomal recessive cerebellar ataxias (ARCAs) are a heterogeneous group of rare neurodegenerative inherited disorders. The resulting motor incoordination and progressive functional disabilities lead to reduced lifespan. There is currently no cure for ARCAs, likely attributed to the lack of understanding of the multifaceted roles of antioxidant defense and the underlying mechanisms. This systematic review aims to evaluate the extant literature on the current developments of therapeutic strategies that target oxidative stress for the management of ARCAs. We searched PubMed, Web of Science, and Science Direct Scopus for relevant peer-reviewed articles published from 1 January 2016 onwards. A total of 28 preclinical studies fulfilled the eligibility criteria for inclusion in this systematic review. We first evaluated the altered cellular processes, abnormal signaling cascades, and disrupted protein quality control underlying the pathogenesis of ARCA. We then examined the current potential therapeutic strategies for ARCAs, including aromatic, organic and pharmacological compounds, gene therapy, natural products, and nanotechnology, as well as their associated antioxidant pathways and modes of action. We then discussed their potential as antioxidant therapeutics for ARCAs, with the long-term view toward their possible translation to clinical practice. In conclusion, our current understanding is that these antioxidant therapies show promise in improving or halting the progression of ARCAs. Tailoring the therapies to specific disease stages could greatly facilitate the management of ARCAs.